Skip to main content
. 2023 Dec 18;12(24):7747. doi: 10.3390/jcm12247747

Figure 3.

Figure 3

Overall survival in selected subgroups. The figure represents a subgroup analysis for OS. Subgroup analyses were conducted for the pN category and the R category. (A) Patients with no nodal metastases (N0, non-myosteatosis vs. myosteatosis: 50 vs. 31 months). (B) Patients with nodal metastases (N1, non-myosteatosis vs. myosteatosis: 18 vs. 7 months). (C) Patients with no residual tumor after resection (R0, non-myosteatosis vs. myosteatosis: 32 vs. 18 months). (D) Patients with residual tumor after resection (R1, non-myosteatosis vs. myosteatosis: 12 vs. 9 months).